The resistant-population cutoff (RCOFF): A new concept for improved characterization of antimicrobial susceptibility patterns of non-wild-type bacterial populations

Journal of Clinical Microbiology

Volumn 53, Issue 6, 2015, Pages 1806-1811

  Valsesia, Giorgia ^a   Hombach, Michael ^a   Maurer, Florian P ^a   Courvalin, Patrice ^b   Roos, Malgorzata ^a   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; IMIPENEM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; EPIDEMIOLOGICAL CUTOFF; ESCHERICHIA COLI; IN VITRO STUDY; INHIBITION KINETICS; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PRIORITY JOURNAL; RESISTANT POPULATION CUTOFF; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; REFERENCE VALUE; REPRODUCIBILITY; STANDARDS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 84929379994     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03505-14     Document Type: Article

References (35)

1. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06.
2. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
3. European Committee on Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0. EUCAST, Växjö, Sweden. http://www.eucast.org/clinical-breakpoints/.
4. Kronvall G, Kahlmeter G, Myhre E, Galas MF. 2003. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect 9:120-132. http://dx.doi.org/10.1046/j.1469-0691.2003.00546.x.
5. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
6. Kronvall G, Giske CG, Kahlmeter G. 2011. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. Int J Antimicrob Agents 38:281-290. http://dx.doi.org/10.1016/j.ijantimicag .2011.04.006.
7. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca- Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MSC, Ostrosky- Zeichner L, Pappas P, Pelaez T, Peman J, Rex J, Szeszs MW. 2012. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 50:2040-2046. http://dx.doi.org/10.1128/JCM.00248-12.
8. Cantón E, Pemán J, Gobernado M, Alvarez E, Baquero F, Cisterna R, Gil J, Martín-Mazuelos E, Rubio C, Sánchez-Sousa A, Serrano C. 2005. Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study. Antimicrob Agents Chemother 49:1604-1607. http://dx.doi.org/10.1128/AAC.49.4.1604-1607.2005.
9. Meletiadis J, Mavridou E, Melchers WJG, Mouton JW, Verweij PE. 2012. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51a sequence analysis. Antimicrob Agents Chemother 56:2524-2529. http://dx.doi.org/10.1128/AAC.05959-11.
10. European Committee on Antimicrobial Susceptibility Testing. 2010. Setting breakpoints for new agents. Standard operating procedure 1.1. EUCAST, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/EUCAST-SOPs/EUCAST-SOP-1.-1-Setting-breakpoints-new-agents-1-June-2013.pdf.
11. Stewart B, Rozen DE. 2012. Genetic variation for antibiotic persistence in Escherichia coli. Evolution 66:933-939. http://dx.doi.org/10.1111/j.1558 -5646.2011.01467.x.
12. Hombach M, Böttger EC, Roos M. 2013. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines. Clin Microbiol Infect 19:E59-E71. http://dx.doi.org/10.1111/1469-0691.12090.
13. European Committee on Antimicrobial Susceptibility Testing. 2014. Zone diameter distributions. EUCAST, Växjö, Sweden. http://mic.eucast.org/Eucast2/.
14. Maurer FP, Courvalin P, Böttger EC, Hombach M. 2014. Integrating forecast probabilities in antibiograms-a way to guide antimicrobial prescriptions more reliably? J Clin Microbiol 52:3674-3684. http://dx.doi .org/10.1128/JCM.01645-14.
15. Matuschek E, Brown DFJ, Kahlmeter G. 2014. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect 20:O255-O266. http://dx.doi.org/10.1111/1469-0691.12373.
16. European Committee on Antimicrobial Susceptibility Testing. 2014. EUCAST disk diffusion manual 2014, version 4.0. EUCAST, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/Manual-v-4.0-EUCAST-Disk-Test.pdf.
17. European Committee on Antimicrobial Susceptibility Testing. 2013. The EUCAST guideline on detection of resistance mechanisms, version 1. EUCAST, Växjö, Sweden. http://www.eucast.org/resistance-mechanisms/.
18. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M. 2012. Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae. Clin Microbiol Infect 18:1194-1204. http://dx.doi.org/10.1111/j .1469-0691.2011.03737.x.
19. Valsesia G, Roos M, Böttger EC, Hombach M. 2015. A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing. J Clin Microbiol 53:1812-1822. http://dx.doi.org/10.1128/JCM.03506-14.
20. Pitout JDD, Laupland KB. 2008. Extended-spectrum β-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
21. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50:133-164. http://dx.doi.org/10.1086/649554.
22. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended- Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167-174. http://dx.doi.org/10.1093/cid/cir790.
23. Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez- Herrera J, Rodríguez-Baño J, Pascual A, Pachón J. 2013. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 57:2109-2113. http://dx.doi .org/10.1128/AAC.02190-12.
24. Livermore DM, Andrews JM, Hawkey PM, Ho P-L, Keness Y, Doi Y, Paterson D, Woodford N. 2012. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 67:1569-1577. http://dx.doi.org/10.1093/jac/dks088.
25. Paterson DL, Bonomo RA. 2005. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 18:657-686. http://dx.doi.org/10.1128/CMR.18.4.657-686.2005.
26. Ho P-L, Chan W-M, Wong SSY, Young K, Tsang KWT. 2002. Bacteremia caused by Escherichia coli producing extended-spectrum betalactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 34:567-573. http://dx.doi.org/10.1080/00365540210147516.
27. Bush K. 2013. The ABCD's of β-lactamase nomenclature. J Infect Chemother 19:549-559. http://dx.doi.org/10.1007/s10156-013-0640-7.
28. Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, Navon Venezia S, Carmeli Y. 2006. Endocarditis caused by extendedspectrum- β-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 50:3179-3182. http://dx.doi.org/10.1128/AAC.00218-06.
29. European Committee on Antimicrobial Susceptibility Testing. 2014. Antibiotic/organism combinations lacking clinical data. EUCAST, Växjö, Sweden. http://www.eucast.org/clinical-breakpoints/antibiotics-lacking-clinical-data/.
30. Winstanley T, Courvalin P. 2011. Expert systems in clinical microbiology. Clin Microbiol Rev 24:515-556. http://dx.doi.org/10.1128/CMR.00061-10.
31. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 47: 1773-1780. http://dx.doi.org/10.1128/JCM.02501-08.
32. Springer B, Calligaris-Maibach RC, Ritter C, Böttger EC. 2008. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J Clin Microbiol 46:4064-4067. http://dx.doi.org/10.1128/JCM.01114-08.
33. Olsen RJ, Long SW, Musser JM. 2012. Bacterial genomics in infectious disease and the clinical pathology laboratory. Arch Pathol Lab Med 136: 1414-1422. http://dx.doi.org/10.5858/arpa.2012-0025-RA.
34. Fournier P-E, Drancourt M, Colson P, Rolain J-M, Scola BL, Raoult D. 2013. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol 11:574-585. http://dx.doi.org/10.1038/nrmicro3068.
35. Lima TB, Pinto MFS, Ribeiro SM, de Lima LA, Viana JC, Júnior NG, Cândido Ede S, Dias SC, Franco OL. 2013. Bacterial resistance mechanism: What proteomics can elucidate. FASEB J 27:1291-1303. http://dx.doi.org/10.1096/fj.12-221127.